Steven K. Libutti, MD, FACS, has been named the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University. When he takes on his new roles in early 2017, Dr. Libutti will be the third permanent Director in the 25-year history of Rutgers Cancer Institute of New Jersey and will take over for Bruce G. Haffty, MD, who has been serving as Interim Director and will continue his role as Chair of Radiation Oncology. In addition to his leadership roles within Rutgers University, Dr. Libutti also will serve as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the health-care system.
Dr. Libutti currently serves as Director for the Montefiore Einstein Center for Cancer Care in New York and is Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an expert in endocrine surgery and management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons.
Dr. Libutti’s clinical practice focuses on gastrointestinal malignancies, including cancers of the liver and pancreas. The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, he is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors.
Responsibilities and Experience
In partnership with RWJBarnabas Health, Dr. Libutti will be recruiting researchers and clinicians to build laboratory sciences and clinical research as well as expanding cancer services across the RWJBarnabas Health network to meet community and academic needs for inpatient and outpatient activities. Along with infrastructure investments, these faculty and leadership recruitments will total more than $100 million in investment in Rutgers Cancer Institute of New Jersey.
Dr. Libutti received his MD from the Columbia University College of Physicians and Surgeons. Following his residency in surgery, he completed a fellowship in Surgical Oncology and Endocrine Surgery in the NCI’s Surgery Branch and was ultimately a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. ■